TY - JOUR

T1 - Pulmonary perfusion with oxygenated blood or custodiol HTK solution during cardiac surgery for postoperative pulmonary function in COPD patients

T2 - a trial protocol for the randomized, clinical, parallel group, assessor and data analyst blinded Pulmonary Protection Trial

AU - Buggeskov, Katrine B

AU - Wetterslev, Jørn

AU - Secher, Niels H

AU - Andersen, Lars W

AU - Jonassen, Thomas Engelbrecht Nordkild

AU - Steinbrüchel, Daniel A

PY - 2013

Y1 - 2013

N2 - Five to thirty percent of patients undergoing cardiac surgery present with chronic obstructive pulmonary disease (COPD) and have a 2- to 10-fold higher 30-day mortality risk. Cardiopulmonary bypass (CPB) creates a whole body systemic inflammatory response syndrome (SIRS) that could impair pulmonary function. Impaired pulmonary function can, however, be attenuated by pulmonary perfusion with oxygenated blood or custodiol HTK (histidine-tryptophan-ketoglutarate) solution.

AB - Five to thirty percent of patients undergoing cardiac surgery present with chronic obstructive pulmonary disease (COPD) and have a 2- to 10-fold higher 30-day mortality risk. Cardiopulmonary bypass (CPB) creates a whole body systemic inflammatory response syndrome (SIRS) that could impair pulmonary function. Impaired pulmonary function can, however, be attenuated by pulmonary perfusion with oxygenated blood or custodiol HTK (histidine-tryptophan-ketoglutarate) solution.

U2 - 10.1186/1745-6215-14-30

DO - 10.1186/1745-6215-14-30

M3 - Journal article

C2 - 23363494

VL - 14

SP - 30

JO - Trials

JF - Trials

SN - 1745-6215

ER -